

Please type a plus sign (+) in this box → ☐

PTO/SB/05 (11-00)

Approved for release through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. 16517.257

First Inventor Sherri M. BROWN, et al.

Title Nucleic Acid Molecules and Other Molecules Associated with the
Gibberellin Pathway

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

Express Mail Label No.

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☐ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 219]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets]
5. Oath or Declaration [Total Pages 15]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63 (d))
(for a continuation/divisional with Box 18 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or
Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☒ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ paper
 - c. ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATIONS PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 C.F.R. §3.73(b) Statement ☐ Power of
(when there is an assignee) Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☒ Request and Certification under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form PTO/SB/35
or its equivalent.
17. ☐ Other: ----

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,
or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No: 09 / 252,974

Prior application information: Examiner ZEMAN, M.

Group / Art Unit: 1631

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied
under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference.
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

28381

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

Name	David R. Marsh				
	June E. Cohan				
Address	ARNOLD & PORTER				
	555 12th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004-1206
Country	USA	Telephone	202-942-5000	Fax	202-942-5999

Name (Print/Type)	David R. Marsh / June E. Cohan	Registration No. (Attorney/Agent)	41,408 / 43,741
Signature			Date
			Sept. 19, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any
comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark
Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for
Patents, Box Patent Application, Washington, DC 20231.

ARNOLD & PORTER

202.942.5000
202.942.5999 Fax
555 Twelfth Street, NW
Washington, DC 20004-1206

September 19, 2001

Box Patent Application

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Continuation Application
Appl. No.: To Be Assigned
Filed: Herewith
For: Nucleic Acid Molecules and Other Molecules
Associated with the Gibberellin Pathway
Inventors: Sherri M. BROWN, *et al.*
Atty. Docket: 16517.257

Sir:

The following documents are forwarded herewith for appropriate action by the U.S.
Patent and Trademark Office.

1. Utility Patent Application Transmittal (PTO/SB/05);
2. U.S. Non-Provisional Application entitled:

Nucleic Acid Molecules and Other Molecules Associated with the Gibberellin Pathway

and naming as inventors:

Sherri M. Brown, Gregory R. Heck and Jingdong Liu;

the application consisting of:

- a. A specification containing:
 - (i) 214 pages of a description prior to the claims;
 - (ii) 4 pages of claims (9 claims); and
 - (iii) a one (1) page abstract;
3. a Statement Regarding Sequence Submission;

4. the sequence listing in computer readable form (*i.e.*, CRF) (1 diskette);
5. a paper copy of the sequence listing (34 pages);
6. a Request and Certification Under 35 U.S.C. 122(b)(2)(B)(i) (PTO/SB/35);
7. Preliminary Amendment;
8. check No. 139309 in the amount of \$710 to cover the basic continuation filing fee; and
9. two (2) return postcards.


Submitted herewith is a sequence listing and a sequence listing in Computer Readable Form (CRF) on diskette, in compliance with 37 C.F.R. §§ 1.52(e), 1.77, and 1.823.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This application is a continuation of prior application no. 09/252,974 filed on February 19, 1999.

Applicants do not believe that any fees other than the basic filing fee (\$710) are due in conjunction with this filing. However, should any additional fees be required, the Patent and Trademark Office is authorized to charge any additional fees or credit any overpayment to Arnold and Porter deposit account 50-1824 referencing matter number 16517.257. This letter is submitted in duplicate.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)
June E. Cohan (Reg. No. 43,741)

Enclosures

09/252,974

**REQUEST AND CERTIFICATION
UNDER
35 U.S.C. 122(b)(2)(B)(i)**

First Named Inventor	Sherri M. BROWN, et al.
Title	Nucleic Acid Molecules and Other Molecules Associated with the Gibberellin Pathway
Atty Docket Number	16517.257

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

September 19, 2001
Date


Signature

David R. Marsh (Reg. No 41,408)

June E. Cohan (Reg. No. 43,741)

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

PATENT APPLICATION SERIAL NO. _____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

01/20/2001 STEUNEL1 00000056 09955216

01 F00101

710.00 OP